36 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials
425
TCRR
Tcr2 Therapeutics Inc
30 May 23
Business combination disclosure
4:21pm
health crises and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention
8-K
i80a8i 7gqih3
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
5tun bbzdfqdvj59b
22 May 23
Business combination disclosure
7:01am
8-K
ln00qgvb f47x
22 May 23
Other Events
6:59am
8-K
EX-99.1
vhtcdaonq2
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
wthf013xpy qek
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
9w470
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
tj34ibtfsj31uc
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
m7c2c9c1dby6l
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm